Showing posts with label Islamic Finance Article. Show all posts
Showing posts with label Islamic Finance Article. Show all posts

Thursday, 4 July 2013

Islamic venture capital: Increasing relevance in promoting entrepreneurship and Islamic finance

This article was originally published in Islamic Finance News Volume:10 Issue:13 dated 26/06/2013


“Despite its origins in the Islamic concept of Mudarabah, Islamic venture capital has yet to take off as a meaningful

sector. Yet it can play a vital role in connecting and developing global markets and encouraging economic growth.

MOHAMMAD ASIF discusses whether the Islamic venture capital might fi nally be ready for lift -off .”


Some of the most infl uential companies in the world today include Google, Yahoo, eBay and Microsoft . A common feature of these companies is that they have been backed by venture capital (VC) firms.


VC is commonly invested in the early or start-up stage of the lifecycle of a company, and is sustained through the company’s growth until a determined exit; mostly in special situations in which there is opportunity for explosive growth. While a fund structure diversifi es risk, these funds are inherently risky.


Historically, VC started from the Islamic concept of Mudarabah, a form of partnership used even before Islam by Arab traders. In the 10th century, the concept of Mudarabah was taken up by the Italians and spread through Europe. About three decades ago, a kind of quantum leap happened and the concept of the modern Islamic bank (Mudarabah in the form of the bank managing the funds from the depositors) emerged.


VC is a risk sharing scheme between investors who provide capital and the entrepreneurs who bring about innovation and undertake activities in the real economy. These two concepts (risk sharing and favoring activities in the real economy) are distinctive features of Islamic finance. Despite this convergence, Islamic finance has yet to fully adopt the VC industry as one of its integral segments.


VC constitutes an important intermediary in the financial system as it provides fi nancing and advisory services to companies that might otherwise encounter diffi culty in attracting capital, as they are typically high risk, young and do not possess sufficient assets

that would be eligible as collateral. The nature of VC as an investment asset class is unique as it has an option-like character in that it has limited downside (the investor cannot lose more than the amount invested) and substantial upside gains. There is always a disconnect between risk and reward for investors. Although the VC industry is flourishing, the failure rate is also high, nearly half of

the companies have negative return. The risks are in the form of:

• Liquidity risk, which is a consequence of the lower liquidity of VC investing;

• Information asymmetry risk, which stems from the fact that VC firms are not subject to the same disclosure requirements as compared to public stocks; and

• Uncertainties surrounding the profitability of the venture capital backed companies.


Despite the failure of the VC industry to neatly outperform publicly traded equities, investments in the former do offer some risk and return features unavailable in the latt er. This implies that VC provides the investors with an avenue for portfolio diversify cation. Within the VC industry and over time, the return is not homogeneous.


The factors that positively affect the performance of a VC firm can be classified as macro and micro – factors that pertain to the environment and factors that are related to the relationships between the firm and the portfolio invested companies. The American VC industry has outperformed the European industry. Micro factors like the degree of involvement and the size of the investment were the determinants.


Many industrialized countries are in the stage of stagnation while some new stars are on the rise and economic center of gravity is shifting. The evolving VC activity in various markets around the world has generated an industry that in many respects is perceived as global, although some global patterns and trends are emerging, the overall development in venture capital markets cannot really be depicted as global. Venture capital activity entails opportunities to restructure regional markets and respond to growing transnational

demands. The pace of globalization of the VC industry is very impressive, which manifests through an increasing internationalization of fundraising for global investment.


Islamic venture capital (IVC) can be defined as a VC industry that conforms to the requirements of Shariah in the area of transactions. The question is: what is required by an IVC firm to distinguish itself and flourish in both a Shariah and market-driven manner?


The sector of Islamic venture capital has been largely ignored until recently because of the lack of an ‘entrepreneur class’ which is essential for the development of a healthy venture capital environment: young, bright people with great business ideas and a  determination to make a success of their business. As the world becomes more of a global marketplace, and as the education and skills level of young people in the region increases, venture investing along Shariah compliant lines may become more common.


When it comes to IVC, we can’t say the greater MENA region has been bereft of venture capital, as countries such as Egypt, Lebanon and even Turkey have long had an entrepreneur class of their own and the VC industry is consequently more developed in these

countries. In much of the GCC there have been impediments to foreigners owning their own businesses outright and this naturally led to an absence of such businesses in the marketplace. As countries like the UAE have introduced ‘free zones’ where foreign nationals

and corporate can own 100% of their own business, the market for venture capital has opened up. Naturally the business idea that will attract Islamic venture capital has to operate within the constraints of Shariah and must not dabble in Haram areas.


The two sides of VC coin are young entrepreneur and venture investors with risk appetite. It is not only about money, it is also about education and expertise which was previously lacking. The combined effect of this has been that the Islamic venture capital industry

was virtually non-existent. The arrival of financial centers such as the Dubai International Financial Center, Malaysia International Islamic Financial Center, Qatar Financial Center, and Bahrain Financial Harbor has opened up the possibility that expert venture capital talent from more mature financial markets could be transplanted into rapidly emerging Islamic finance markets and bring with it the intellectual wherewithal to do lucrative Islamic venture capital deals.


Islamic finance is now at the threshold of a new dimension in which the industry has an increased capability to strengthen international fi nancial interlinks between nations. IVC has the potential to contribute towards the efficient mobilization and allocation

of funds across regions. Prospects for the Islamic fi nance industry are bright owing to strong demand for financial services from a large segment of the world’s 1.4 billion Muslims and the need to effectively channel rising international savings, including those of high-networth individuals.


Islamic venture capital funds face little or no hindrance from regulatory bodies in terms of Shariah compliance because the only difference from conventional VC is in the selection of firms. Hence the scope of IVC in terms of territory is beyond the Islamic banking sector where regulatory hindrances are high. Also Islamic banking and Islamic venture capital can benefit each other. IVC can promote entrepreneurship and hence the funded firms may be obliged and motivated to use services of only Islamic banks. On the other hand, Islamic banks can become source of funds for Islamic venture capital funds.


IVC firm partnership may take either the Musharakah structure with a ‘selldown’ model where the general partners will eventually buy out the shares of the limited partners at a price valued upon the exit proceeds (i.e. market value) or the Mudarabah structure whereby the partnership is terminated upon the exit. The choice of Musharakah or Mudarabah partnerships depends on whether the general partners will also invest their own funds or not. The integration of this high risk, high return segment into the Islamic finance industry will be of nature to offer a diversify cation and an investment avenue to investors with high risk appetite.


 


Mohammad Asif is the Director of  JaZaa Financial Advisory.


He can be contacted at mohammadasif@jazaafinancials.com



Islamic venture capital: Increasing relevance in promoting entrepreneurship and Islamic finance

Thursday, 14 February 2013

Booming Sukuk

A recent report published by KFH research revealed that total Sukuk issuance by end of 2012 reached $131bn with 54% increase than 2011. The sukuk market is witnessing extensive growth in the Islamic Finance sector. It has finally broke out from its shell of being a niche market instrument to enter a new era as an alternative to conventional bonds. Analysts are expecting the demand of Sukuk to reach upto $421 billion by 2016. The demand seems to be rising because of investor’s inclination towards Islamic Capital market. Investors expect 50 percent of their portfolios to be allocated to Islamic finance investments, out of which an average of 35 to 40 percent, would be allocated to Sukuk. The leading countries in Sukuk issuance are: Malaysia, Saudi Arabia, UAE, and Indonesia. 

Malaysia dominated among them in terms of amount issued, accounting for a 90.2 per cent market share. MENA region, and more specifically the GCC region, has been a key market for issuances this year despite no participants from Qatar and Kuwait.In the UAE, the second largest Arab economy, Abu Dhabi’s Al Hilal bank issued a $500mn sukuk this year. The other reason for the growth of Sukuk is due to the declining yields for both corporate and sovereign bonds, the rarity of high quality yielding papers and the flight to fixed income safety amid more concerns emerging from Europe. The Islamic bond got a boost after it was rated by S & P as reliable for GCC companies and infrastructure project. GCC economies are among the leading global spenders on infrastructure, which should in principle open important new opportunities for Shariah-compliant capital market development.The improvement in market conditions, and gradual recovery of the global economy and investor sentiment will also drive the demand for sukuk deals.
The study also suggests certain deficiencies in the existing Sukuk structures and their associated documentation, investor rights, transparency, and illiquidity in the secondary market.  Spread between demand and supply is expected to widen more than $280 billion within the next four years. These challenges in the Sukuk market will act as impediments in the growth of Islamic finance market. To free the arteries of the Islamic capital market and subsequently enrich its tributaries and downstreams, there is a need for practical studies that address its challenges, and that will provide a clearer picture of its current and forecasted status.
Few potential investors are reluctant to invest in Sukuk due to their poor featured structure and low yield as compared to conventional bonds. For example the most common Sukuk structureprevalent in the market is Al-Ijara that requires a huge investment irrespective of less return compared to high returns on the same investment in conventional bonds. Islamic finance experts have replaced this with musharaka and mudaraba bonds with good returns and high flexibility.
The point to be noted is that the major chunk of growth that was seen during the year 2012 was due to Euro crisis and global credit crunch. The policy revamp favoring the conventional economy will turn the growth arrow mark back on track. Eventually the financial market will also show positive turns and increase in bond investors. Therefore Islamic bonds to retain its growth and meet its expected return must focus on how far they can compete with the conventional bonds in terms of yields and attributes. The niche opportunity that Sukuk has can be converted into a wider opportunity only if trust worthiness of the customers are unhindered and retained for a long time. Not to forget, the most important principle of the all these developments and changes must be in compliance with the Shariah.

Booming Sukuk

Monday, 11 February 2013

Pharma Industry: The Growing Potential


Research Analyst, TASIS
India is one of the fastest growing markets for the pharmaceutical industry. It accounts for 8% of total global pharmaceutical production. The size of domestic formulation market is USD 8.7 billion. Exports constitute major portion of sales of the Indian Pharmaceutical companies (Exhibit 4). India’s exports of drugs, pharmaceutical and fine chemicals is around USD 11 billion for the year ended March 2012, according to data compiled by Pharmaceutical Exports Council of India (Pharmexcil). The major country for export of Indian pharmaceutical product is the US which accounts for 22% of total export. It is followed by UK, Germany, Russia and South Africa. The major pharmaceutical companies of India are focussing the generic drug market in these countries. The major exporters to these countries are Dr Reddy’s, Sun Pharmaceutical, Ranbaxy, Lupin and Cadila Healthcare.
Below we give snapshot of the pharma industry business model before moving to the market analyses.
Generic: Drug produced and distributed without any patent protection is known as Generic. It is the low cost version of patented drug, and the companies produce generic version once the patent period for a drug expires. Introduction of generic drug in the market provides the medicines to the consumer at affordable prices. Indian pharmaceutical companies are faring well in the generic market.
Generic generic or unbranded generic market is prominent in the US, UK and some other Europeans countries. In these countries Doctors instead of prescribing the brand, prescribes the molecule for a particular disease. More than 90% population in these countries have medical insurance, therefore the insurance company decides the drug to be used. Obviously they pick up the low cost drug.
The main market for branded generic is India, Brazil, Russia, Mexico etc. Here the doctors prescribe the brand name of a drug for a particular disease. For e.g. in India doctor will prescribe either Crocin or Metacin or some other brand name for molecule Paracetamol. Consumers prefer to buy the exactly prescribed brand.
  • NCE (New Chemical Entities): It is the discovery of new drugs which requires great time and huge investments. Indian Pharmaceutical companies are not very active in the area due to lack of resources.
  • CRAMS (Contract Research and Manufacturing services): It is like outsourcing; major world pharmaceutical companies outsource their manufacturing works to reduce the cost so that they could focus on new drug discovery and strategies. India is emerging as the potential CRAM market. The estimated market size of CRAM in India is USD 4 billion. Multinationals like Astra Zeneca, Pfizer, Eli lily, GSK, Merck, Allergan, are the major companies which outsource their demand from Indian CRAM companies.
Domestic Market:
The Indian domestic pharmaceutical market is around USD 8.7 billion. It is growing at CAGR of 14-15% over the past 5 years. Currently India is the third largest market in the world in terms of volume and 14th largest in terms of value. According to PWC report the Indian pharmaceutical industry will reach USD 74 billion by 2020. Rising household income, changing lifestyle and increased penetration in smaller towns and rural areas are the major factors for growth of the domestic pharmaceutical market. 100% FDI in this sector has been approved which promises greater potential for the industry.
On the basis of therapeutic areas, the pharmaceutical market could be divided in two segments:
  • Acute Segment: Includes the disease which last for short duration. It includes the therapies like anti-infective, pain killers etc.
  • Chronic Segment: The diseases are of recurring in nature and the major causes of such diseases are the lifestyle of human being. In most of the cases, the patient requires regular consumption of medicine. The therapies under chronic segment are anti-diabetics, cardiovascular disease, cancer etc.
In India Acute segment captures 73% of the total pharmaceutical market (ICRA). With the changing lifestyle, this market is expected to grow as there will be rise in the chronic disease. According to IMS health report, the chronic segment will comprise more than 50% of the market by 2020.
Foreign Market:
US with the market size of more than USD 323 billion is the largest market for pharmaceutical industries. It provides huge opportunity for the generic market.  According to ICRA (Indian pharmaceutical Sector Industry Update March 12), patented drug worth of USD 100 billion will expire in US in the next five years. This would give huge opportunity for the Indian pharmaceutical industry to expand their generic market base in US. Also the US government healthcare reform which aimed at reducing the spending on healthcare and providing cover to larger section is the stimuli for growth of generic market. To grab the opportunity many Indian companies have filed Abbreviated New Drug Application (ANDA) for selling generic product in US.  The table below gives the details of ANDA filing status of Indian Pharmaceutical companies.
Company
Filed
Approved
Pending Approval
% Pending
Sun Pharma
377
225
152
40%
Ranbaxy
205
135
70
34%
Aurobindo
197
133
64
32%
Dr Reddy’s
179
103
76
42%
Lupin
148
48
100
68%
Cadila
130
65
65
50%
Glenmark
109
69
40
37%
Exhibit 2; Source: Indian pharmaceutical Sector, Industry Update, ICRA, Mar 2012
The European generic market is different from that of US generic market, it is more diverse. UK, Germany and Netherland have relatively high penetration of generic market whereas France, Italy and Spain have low penetration. Due to the current uncertainty in the EU, governments have introduced austerity measures which aim at reducing the health care spending by substantial amounts. This has led to a shift from branded drugs to unbranded generics. How far this opportunity can be capitalised by Indian pharma companies is the million dollar question. Among leading players, Wockhardt has the highest exposure to Europe with over 37% contribution to its revenues, followed by  Dr. Reddy’s 21% contribution (owing to its acquisition of Betapharm in Germany), Ranbaxy, Cipla and Intas Pharma have considerable presence in the European markets.
Japan is the second largest pharmaceutical market in the world. The penetration of generic drug in Japan is low (23%) and ranks sixth largest generic market. Healthcare reforms initiated by government is gradually opening the market for generic drug. Among Indian companies, Lupin, Ranbaxy, Torrent Pharma and Cadila Healthcare are among the front runners in this market. While Ranbaxy (by virtue of its Japanese parent, Daiichi Sankyo) is exploring a hybrid model for the Japanese market, Lupin has recently strengthened its presence by acquiring another company in the injectables segment. The other emerging market for generic drugs is Russia, Brazil, and South Africa.
The future of Indian pharmaceutical industry looks favourable as there would be increased demand for the generic drugs both within India as well as foreign markets. Below tables give the performance detail of the Pharmaceutical Industry and some of its top players.
Ratios
2012
2011
2010
EBITDA Margin (%)
21.38
22.08
21.75
ROA (%)
10.57
18.39
11.06
ROE (%)
13.28
27.77
18.46
Asset Turnover(x)
0.91
0.9
0.95
Sales/Fixed Asset(x)
1.74
1.83
1.88
Working Capital/Sales(x)
5.89
3.21
2.21
Net Sales Growth (%)
15.5
15.94
14.95
Exhibit 3; Source: Ace Equity

Company Name
Year
Net sales (USD million)
PBDITA (USD billion)
EBDITA/ Net Sales
Export/ Net Sales
Ranbaxy Laboratories Ltd.
31-12-2011
  1,525.55
     321.70
21%
72%
Cipla Ltd.
31-03-2012
  1,393.28
     361.84
26%
53%
Dr. Reddy’S Laboratories Ltd.
31-03-2012
  1,335.12
     373.88
28%
74%
Lupin Ltd.
31-03-2012
  1,070.53
     230.44
22%
59%
Aurobindo Pharma Ltd.
31-03-2012
     855.38
        61.85
7%
70%
Mylan Laboratories Ltd.
31-03-2012
     789.39
     163.98
21%
87%
Jubilant Life Sciences Ltd.
31-03-2012
     526.08
        93.97
18%
52%
Cadila Healthcare Ltd.
31-03-2012
     517.26
     183.98
36%
52%
Wockhardt Ltd.
31-03-2012
     510.72
     146.05
29%
54%
Sun Pharmaceutical Inds. Ltd.
31-03-2012
     480.08
     432.96
90%
61%
Glaxosmithkline Pharmaceuticals Ltd.
31-12-2011
     475.55
     216.58
46%
3%
Ipca Laboratories Ltd.
31-03-2012
     469.42
     104.53
22%
58%
Torrent Pharmaceuticals Ltd.
31-03-2012
     414.70
        93.82
23%
39%
Divi’S Laboratories Ltd.
31-03-2012
     368.67
     152.33
41%
88%
Exhibit 4; Source: CMIE

Note: This article was published in BSE Broker’s Forum Newsletter” Forum Views”, Vol. 1, Issue No:9, Mumbai, December 2012.